Ronald Blue Trust, Inc. Biotechnology

Ronald Blue Trust, Inc.

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
XFOR X4 Pharmaceuticals, Inc	$272M	$2,000 0.0% of portfolio	8,520	Q2 2022 New
HALO Halozyme Therapeutics, Inc.	$7.43B	$2,000 0.0% of portfolio	46	Q1 2025 New
KRYS Krystal Biotech, Inc.	$3.36B	$1,000 0.0% of portfolio	9	Q1 2025 Added 200.0%
SAGE Sage Therapeutics, Inc.	$388M	$0 0.0% of portfolio	2	Q4 2024 Reduced 99.63%
DAWN Day One Biopharmaceuticals, Inc.	$513M	$0 0.0% of portfolio	44	Q1 2025 New
CRSP Crispr Therapeutics Ag	$3.01B	$0 0.0% of portfolio	6	Q4 2024 Reduced 99.63%
SWTX Spring Works Therapeutics, Inc.	$2.92B	$0 0.0% of portfolio	21	Q1 2025 New
ABSI Absci Corp	$257M	$0 0.0% of portfolio	100	Q1 2025 New
CLDX Celldex Therapeutics, Inc.	$934M	$0 0.0% of portfolio	23	Q1 2025 New
ARWR Arrowhead Pharmaceuticals, Inc.	$1.76B	$0 0.0% of portfolio	27	Q1 2025 New
GLPG Galapagos Nv	$1.89B	$0 0.0% of portfolio	10	Q4 2024 Reduced 98.62%
IMCR Immunocore Holdings PLC	$1.7B	$0 0.0% of portfolio	6	Q4 2024 Reduced 97.87%
AKRO Akero Therapeutics, Inc.	$2.37B	$0 0.0% of portfolio	13	Q4 2024 Reduced 81.69%
NTLA Intellia Therapeutics, Inc.	$585M	$0 0.0% of portfolio	63	Q1 2025 Added 530.0%
OCGN Ocugen, Inc.	$182M	$0 0.0% of portfolio	500	Q1 2024 New
NVAX Novavax Inc	$568M	$0 0.0% of portfolio	50	Q3 2024 Reduced 54.13%
BCYC Bicycle Therapeutics PLC	$254M	$0 0.0% of portfolio	11	Q4 2024 Reduced 99.08%
VCYT Veracyte, Inc.	$1.9B	$0 0.0% of portfolio	12	Q4 2024 Reduced 99.44%

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

Stay updated on Ronald Blue Trust, Inc. with notifications on news.